Get the Stockscreener App
13.76
0.44%
0.06
After Hours:
13.85
0.09
+0.65%
Syndax Pharmaceuticals Inc stock is traded at $13.76, with a volume of 4.08M.
It is up +0.44% in the last 24 hours and down -11.79% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$13.70
Open:
$13.61
24h Volume:
4.08M
Relative Volume:
1.48
Market Cap:
$1.19B
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-4.6486
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
+4.96%
1M Performance:
-11.79%
6M Performance:
+0.22%
1Y Performance:
-27.50%
1-Day Range:
$13.36
$14.36
1-Week Range:
$13.02
$14.36
52-Week Range:
$8.58
$22.50
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
13.76 | 1.18B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Resumed | H.C. Wainwright | Buy |
| Sep-10-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Aug-05-25 | Reiterated | BTIG Research | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Syndax Pharmaceuticals Q3 Earnings: EPS of -$0.70 Beats Estimate, Revenue of $45.9M Misses Estimate - GuruFocus
Syndax: Q3 Earnings Snapshot - News-Times
Syndax Pharmaceuticals Grows Revenue As Wall Street Stays Bullish - Finimize
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Syndax Pharmaceuticals falls as Q3 revenue misses estimates - Investing.com
SNDX: Syndax Pharmaceuticals to Showcase Promising Data at ASH 2 - GuruFocus
Is Syndax Pharmaceuticals Inc. stock poised for growth2025 Technical Overview & Low Volatility Stock Recommendations - newser.com
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025 - The Manila Times
Syndax Announces Compelling Revuforj® (revumenib) and - GlobeNewswire
Syndax (NASDAQ: SNDX) to present Revuforj and Niktimvo data in 23 ASH 2025 abstracts - Stock Titan
How Syndax Pharmaceuticals Inc. stock performs in rate cut cycles2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Using Ichimoku Cloud for Syndax Pharmaceuticals Inc. technicals2025 Big Picture & Entry and Exit Point Strategies - newser.com
Leading vs lagging indicators on Syndax Pharmaceuticals Inc. performanceJuly 2025 Short Interest & Entry Point Confirmation Alerts - newser.com
Is Syndax Pharmaceuticals Inc. (1T3) stock undervalued by metricsMarket Activity Recap & Weekly Momentum Picks - newser.com
AlphaQuest LLC Sells 18,370 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Applying Wyckoff theory to Syndax Pharmaceuticals Inc. stockBreakout Watch & Verified Technical Trade Signals - newser.com
Detecting support and resistance levels for Syndax Pharmaceuticals Inc.Jobs Report & Verified Swing Trading Watchlist - newser.com
Is it too late to sell Syndax Pharmaceuticals Inc.Weekly Trade Summary & Growth-Oriented Investment Plans - newser.com
Will Syndax Pharmaceuticals Inc. stock maintain momentum in 2025Portfolio Value Report & Accurate Trade Setup Notifications - newser.com
Is Syndax Pharmaceuticals Inc. stock reversal real or fakeMarket Trend Report & Community Verified Watchlist Alerts - newser.com
How Syndax Pharmaceuticals Inc. stock performs in stagflationJuly 2025 Chart Watch & Verified Momentum Watchlists - newser.com
Is Syndax Pharmaceuticals Inc. showing signs of accumulationMarket Volume Summary & AI Driven Stock Movement Reports - newser.com
Syndax Pharmaceuticals (SNDX) Q3 Earnings Preview: Key Expectati - GuruFocus
Kura Oncology's Ziftomenib Poised For Differentiation (NASDAQ:KURA) - Seeking Alpha
How risky is Syndax Pharmaceuticals Inc. stock nowJuly 2025 Recap & Free Technical Pattern Based Buy Signals - newser.com
Y Intercept Hong Kong Ltd Makes New Investment in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
B. Riley Issues Optimistic Estimate for SNDX Earnings - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Report Previe - GuruFocus
Syndax Pharmaceuticals Hits Day Low at $13.03 Amid Price Pressure - Markets Mojo
Syndax Pharmaceuticals’ Promising AML Study Update: Key Insights for Investors - TipRanks
Is Syndax Pharmaceuticals Inc. (1T3) stock considered safe havenJuly 2025 Sentiment & Fast Moving Stock Watchlists - newser.com
Why Syndax Pharmaceuticals Inc. stock is rated strong buyJuly 2025 Selloffs & Weekly Momentum Picks - newser.com
Published on: 2025-10-30 09:56:20 - newser.com
Syndax Pharmaceuticals Launches Promising Phase 3 AML Study with Revumenib - MSN
Syndax Announces Participation in November Investor Conferences - The Manila Times
Is Syndax Pharmaceuticals Inc. (1T3) stock a buy during volatile marketsEarnings Risk Summary & Smart Investment Allocation Insights - newser.com
Syndax (Nasdaq: SNDX) to join fireside chats at UBS, Guggenheim, Stifel, Jefferies - Stock Titan
Syndax Pharmaceuticals (SNDX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Is Syndax Pharmaceuticals Inc. stock a safe investment in uncertain marketsDividend Hike & AI Driven Stock Price Forecasts - newser.com
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):